Elizabeth Wu

Survey of hepatitis B knowledge and stigma among chronically infected patients and uninfected persons in Beijing, China

Hepatitis B virus (HBV) infection carries substantial stigma in China. We surveyed HBV knowledge and stigma among chronic hepatitis B (CHB) patients and persons without HBV infection in Beijing, China.

The higher prevalence of truncal obesity and diabetes in American than Chinese patients with chronic hepatitis C might contribute to more rapid progression to advanced liver disease

Chronic hepatitis C virus (HCV) infection is the leading cause of cirrhosis and hepatocellular carcinoma (HCC) in the United States (US) and an emerging cause in China.

Patient Education Improves Patient Knowledge and Acceptance on Antiviral Therapy of Hepatitis C in Rural China

It is estimated that 130–150 million people are chronically infected with hepatitis C virus (HCV) worldwide. During the late 1980s and early 1990s, illegal commercial plasma or blood donation practices were common in selected rural areas of China, which caused a rapid spread of HCV infection. Cross‐sectional studies have showed that the prevalence rates of HCV infection in former paid plasma or blood donors varied from 9.6% to 72.8%. Chronic HCV infection can cause cirrhosis, liver failure, and hepatocellular carcinoma (HCC), and is a major global health problem. Eradicating HCV can prevent decompensation of cirrhosis, HCC, and death.[1] The availability of direct‐acting antiviral agents (DAAs) has significantly increased sustained virological response rates and decreased the complexity and adverse effects of HCV treatment. Much of the current debate on HCV treatment focuses on the high cost of these drugs, but even if the cost of HCV drugs is affordable, treatment would only benefit infected persons who have been diagnosed, have access to care, and wish to be treated. Despite the availability of effective treatments for HCV, globally no more than 15% of those infected are aware of their status and no more than 20% of those diagnosed have been treated.

Mo1047 A Comparative Study of Decision Making Preferences in Patients With Liver Disease in the United States and Urban and Rural China

after transplant and for biopsies with moderate or severe acute cellular rejection. Survival was documented at intervals of 1 month, 1, 3 and 5 years for those reaching the respective time points. Cochran-Armitage trend test was used for sub-group analysis. Chi-Square test and Fischers exact test were used for condensed group analysis. Results A total of 501 patients were evaluated. 18 patients expired during transplant admission and were only included in survival analysis. 364 patients (70.7%) lived less than 50 miles from our center whereas 137 patients (27.3%) lived 50 or more miles away. Survival at 1 month and 1 year was significantly higher for patients living less than 50 miles (97.8% and 91.2% respectively) versus 50 or more miles (93.4% and 83.9%) (p = 0.024 and 0.019). Survival rates at 3 and 5 years for those living less than 50 miles were 80.9% and 71% versus 71% and 66% for 50 or more miles (p = 0.2 and 0.378). Incidence of rejection was higher in those living less than 50 miles (17.4%) versus those living at a greater distance (10.2%) (p = 0.050). However, 30 day re-admission rates were similar in both groups at 38% and 39% (p = 0.717). Conclusion Our study suggests recipients living more than 50 miles from our center have decreased survival after transplant in spite of lower rates of rejection. These results show clear differences in outcomes based on location which will lead to further investigations to address the underlying causes for increased mortality in those living further from our center.

P411 A SHORTER ESTIMATED DURATION OF INFECTION IN CHINA VERSUS US MAY ACCOUNT FOR THE LOWER PREVALENCE OF HCV-RELATED CIRRHOSIS AND HCC IN CHINA

P411 A SHORTER ESTIMATED DURATION OF INFECTION IN CHINA VERSUS US MAY ACCOUNT FOR THE LOWER PREVALENCE OF HCV-RELATED CIRRHOSIS AND HCC IN CHINA H. Rao, E. Wu, S. Fu, B. Feng, R. Fei, A. Lin, M. Chan, R.J. Fontana, L. Wei, A.S. Lok. Peking University People’s Hospital, Peking University Hepatology Institute, Peking University Health Science Center, Beijing, China; Department of Internal Medicine, Division of Gastroenterology, University of Michigan Health System, The Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI, United States E-mail: rao.huiying@163.com